AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03673384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyzal Oral Product
Description: used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
Study NCT03673384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Furoate
Description: used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
Study NCT03673384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
Study NCT00644371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin)
Description: Conditioning Regimen~1. Rituximab, 250 mg/m2 on days -21 and -14.~2. Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~* Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~* Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~* Melphalan 70 mg/m2/day on day -2 as a 15-min infusion.
Study NCT02101320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRECAM
Description: using the camera during the surgery
Study NCT03624270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral arsenic Trioxide, ATRA and ascorbic acid
Description: Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
Study NCT04512027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolectin-M; a (1-6)-alpha-D-Mannopyranose class
Description: A treatment to decrease viral load, detected through digital droplet PCR, in mild to moderate cases of RT-PCR positive COVID-19
Study NCT04512027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Currently approved standard of care for patients without symptoms requiring hospitalisation will be provided to all.
Study NCT03273127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol
Description: A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
Study NCT03273127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abediterol matching placebo without any pharmacological activity.
Study NCT00185211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
Study NCT00185211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
Study NCT00265083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: golimumab
Description: 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
Study NCT00265083 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab (CNTO 148); placebo
Description: SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
Study NCT00265083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: golimumab
Description: 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
Study NCT03916237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home remediation
Description: Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
Study NCT01841359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: See description above (arm description).
Study NCT04393805 — intervention group
Intervention type: DRUG
Intervention: Low Molecular Weight Heparin
Description: Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin
Study NCT00721461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V930
Description: Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
Study NCT03935659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Pressure Wound Therapy
Description: Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
Study NCT03935659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Care
Description: Standard sterile gauze coverage of the primarily closed groin wound.
Study NCT03524937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELATONIN (HIGH DOSE)
Description: Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
Study NCT03524937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MELATONIN (LOW DOSE)
Description: Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
Study NCT03524937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
Study NCT00528437 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Description: 13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
Study NCT04627220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: taken venous sample
Description: Venous blood samples taken during the operation and at the 48th hour after the operation will be examined after appropriate procedures.
Study NCT04275661 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound (US) bi-level erector spinae block
Description: nerve block
Study NCT04275661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) bi-level erector spinae block
Description: nerve block
Study NCT04275661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levobupivacaine
Description: 20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
Study NCT04275661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: 20 ml 0.25% levobupivacaine injected into fascial plane deep to erector spinae muscle
Study NCT04275661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 2 mg /kg ketamine.injected into fascial plane deep to erector spinae muscle
Study NCT04275661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 2mg/kg Magnesium Sulfate .injected into fascial plane deep to erector spinae muscle
Study NCT03372369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: View CDC Poster
Description: The poster designed by the CDC to explain contraceptive effectiveness.
Study NCT03372369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: View Patient-Centered Poster
Description: The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
Study NCT02094937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
Study NCT02094937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100 mcg
Description: FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
Study NCT02094937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 250 mcg
Description: FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
Study NCT02094937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg
Description: FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
Study NCT02094937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate Placebo
Description: Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
Study NCT02094937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Placebo
Description: Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
Study NCT04317781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study NCT00353938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-methylenedioxymethamphetamine (125 mg)
Description: Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2.5 hours later they will receive 62.5 mg MDMA orally.
Study NCT00353938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methyelendioxymethamphetamine (25 mg)
Description: Participants will receive a 25 mg MDMA orally, and if investigator and participant agree, 2.5 hours later they will receive 12.5 mg MDMA orally.
Study NCT00353938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy performed by a team of two co-therapists
Study NCT00353938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy performed by a team of two co-therapists
Study NCT02624973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Study NCT02281630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KWA-0711
Study NCT02281630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04645238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Static hamstring stretching exercise lasting 30 seconds and 10 repetitions under the supervision of the physiotherapist
Study NCT04645238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF Stretching
Description: PNF hold-relax stretching technique that consists of 10 seconds isometric contraction, 30 seconds hamstring stretching and 10 repetitions under the supervision of the physiotherapist
Study NCT04537702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Streamlined Education
Description: After completion of the baseline surveys, the SG subjects will watch an approximately eight minute long genetics education video. This video will be made with the assistance of Duke University genetic counselors and gynecologic oncology providers. It will consist of a discussion of genes and mutations, the recommendation of universal testing for high grade epithelial ovarian cancer, a review of genes associated with ovarian cancer predisposition, the possibility of uncertain results including variants of undetermined significance, the potential for undetected mutations in known or unknown cancer susceptibility genes, the potential impact on personal treatment and on family members, the possibility of genetic discrimination and the legal protection of genetic information.
Study NCT04537702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: The TG subjects will then meet with the genetic counselor at the previously scheduled appointment time. During this visit, they will receive approximately thirty to sixty minutes of counseling regarding genetic testing and potential results. The discussion is based on the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines of informed consent for genetic testing. After counseling, participants will be given the option to undergo a multi-gene panel genetic test either via saliva or blood sample. Those who agree to testing will also complete the standard genetic testing consent form. As per standard practice of the clinical genetic service at DCI, patients will also be asked to provide consent for somatic tumor testing of surgical specimen (non-cytologic).
Study NCT03256383 — intervention group
Intervention type: DEVICE
Intervention: Lead testing
Description: Fingerstick
Study NCT00618423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
Study NCT00618423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
Study NCT01623830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
Study NCT01623830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
Study NCT04448691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CCTA
Description: requested follow up CCTA
Study NCT01792284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT02624973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant letrozole (postmenopausal women)
Study NCT01792284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
Study NCT02624973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen + goserelin (premenopausal women)
Study NCT02624973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant palbociclib (if palbociclib given neoadjuvant)
Study NCT02624973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Epirubicin+ Cyclophosphamide
Study NCT02279576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg/day continuously administered.
Study NCT02279576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
Study NCT00803946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablets, 800 mg
Study NCT03124381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cleanser, Acne Mask
Description: A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
Study NCT03124381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleanser, Gel-Cream, Acne Mask
Description: A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
Study NCT03995303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCP and home-delivered meals
Description: The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
Study NCT00297479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT Group Therapy
Description: In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
Study NCT00297479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 6 weeks of nicotine patch therapy
Study NCT00297479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 6 weeks of nicotine patch therapy
Study NCT00297479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
Study NCT01517802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
Study NCT01517802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
Study NCT04020770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrating ball
Description: Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
Study NCT00996996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
Description: Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass.
Study NCT00534196 — intervention group
Intervention type: RADIATION
Intervention: Permanent iodine-125 (Brachytherapy)
Description: Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
Study NCT01309620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: Zinc gluconate (GNC, USA), 100 mg twice daily
Study NCT01309620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Twice Daily
Study NCT00297479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Therapy
Description: In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline